Endothelial cells deliver a vital contribution to the maintenance of hemostasis by constituting
an anatomical as well as functional barrier between the blood and the rest of the body. Apart …

In more than half of the individuals with a clinically relevant bleeding tendency who are
referred to hemostasis experts, no biological etiology can be found after extensive laboratory …

Background Patient-reported outcomes measurement information system (PROMIS)
measures can be used to measure patient-reported outcomes. PROMIS measures, including …

One of the most used and versatile methods to study number, dimensions, content and
localization of secretory organelles is confocal microscopy analysis. However, considerable …

Background There are great expectations for the potential role of gene therapy in the
treatment of hemophilia. At the same time, developments in the field of hemophilia gene …

Background Endothelial colony-forming cells (ECFCs) derived from patients can be used to
investigate pathogenic mechanisms of vascular diseases like von Willebrand disease …

Introduction Emicizumab effectively prevents bleeding in people with haemophilia A
(PwHA), but is a burden for national healthcare budgets and consequently may limit access …

Patients with severe and sometimes moderate hemophilia B are prophylactically treated with
factor IX concentrates to prevent bleeding. For some time now, various extended terminal …

Abstract Background Glycoprotein (GP) VI is a platelet-specific collagen receptor required
for platelet activation during hemostasis. Platelet reactivity toward collagen is routinely …

Introduction Emicizumab effectively prevents bleeding in people with haemophilia A
(PwHA), but is a burden for national healthcare budgets and consequently may limit access …